Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients

Chronic Hepatitis C Virus Infection Clinical Trial

Official title:

A Phase I/IIa Open-Label, Dose Ranging, Parallel, Safety, Tolerability and Efficacy Study of i.m. Administered CHRONVAC-C® in Combination With Electroporation in Chronic HCV Genotype 1 Infected and Treatment Naïve Patients With Low Viral Load

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00563173
• Other study ID #: CVC-201
• Secondary ID: EudraCT No. 2007
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• First received: November 23, 2007
• Last updated: February 9, 2010
• Start date: October 2007
• Est. completion date: April 2010

Study information

• Verified date: February 2010
• Source: Tripep AB
• Contact: n/a
• Is FDA regulated: No
• Health authority: Sweden: Medical Products Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate if the DNA vaccine CHRONVAC-C® intended for future treatment of Hepatitis C infections is safe and tolerated when administered to HCV infected individuals with a low viral load. In addition the capability of the vaccine to induce an immune response and the effect on viral load will be studied. In order to increase the uptake of the vaccine the intra muscular injection is combined with electroporation, meaning that a brief electric field is applied to the injection site resulting in temporary pores in the cell membranes that allows the vaccine to enter the cells.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 12
• Est. completion date: April 2010
• Est. primary completion date: April 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Male or female patient 18 -65 years of age with a known chronic hepatitis C infection.

• Genotype 1 infection.

• Viral load equal to or less than 800.000 IU/mL.

• BMI less than 30.

• Considered probable that the deltoid muscles (left and right) of the patient will be reached at vaccination using a 12.7 mm cannula for injection and a 15 mm applicator tip for electroporation.

• Written informed consent obtained, and a copy provided to the patient.

• Patient legally competent and able to communicate effectively with the study personnel.

• Patient likely to co-operate and attend the clinic at the appointed times during the study.

Exclusion Criteria:

• Patient having clinically significant concomitant diseases other than HCV in the medical history to the discretion of the investigator.

• Patient having clinically significant findings on physical examination, vital signs, ECG or clinical laboratory evaluations to the discretion of the investigator.

• Patient having clinical or biochemical signs of cirrhosis.

• Positive hepatitis B surface antigen (HBsAg).

• Positive HIV antigen or antibody test.

• Patient having an ongoing and/or known viral infection other than HCV that requires treatment and/or special medical intention.

• Patient having received previous treatment for HCV.

• Radiation therapy or cytotoxic chemotherapeutic agents within 4 weeks prior to the first dose of study drug.

• Treatment with immunomodulating agents such as systemic corticosteroids, IL-2, IFN-alpha, IFN-beta, IFN-gamma within 4 weeks prior to the first dose of study drug.

• Treatment with NSAID within 10 days of the first dose of study drug.

• Immunization within 30 days of the first dose of the study drug.

• Patient having received an investigational drug product, or been enrolled in other investigational drug protocols within a period of 30 days prior to receiving the first dose of the study drug.

• Prior treatment with DNA therapy.

• Known allergy towards vaccines.

• Known abuse of alcohol, drugs or pharmaceuticals.

• History, signs or symptoms of a cardiac disease.

• Presence of an implantable pacemaker.

• Any metal implants within the treatment areas (close to the right and/or left deltoid muscles).

• Diagnoses of a serious psychiatric illness which may influence study participation.

• Female patient who is breast feeding.

• Female patient not clinically sterile (hysterectomy, tubal ligation or postmenopausal (amenorrhea > 1 year and FSH > 30 mU/ml) OR if not clinically sterile unwilling to use a reliable contraception method.

• Patient with a positive urine pregnancy test.

• Male patient unwilling to use condom for active prevention of pregnancy from first vaccination to 4 months after last injection.

• Patient or their immediate families being an investigator or site personnel directly affiliated with this study. Immediate family is defined as a spouse, parent, child or sibling, whether biologically or legally adopted.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Hepatitis C Virus Infection
• Hepatitis C
• Hepatitis C, Chronic
• Hepatitis, Chronic
• Virus Diseases

Intervention

Drug:
• CHRONVAC-C®
DNA vaccine, solution for injection, i.m. administration in combination with electroporation

Locations

Country	Name	City	State
Sweden	Department of Gastroenterology and Hepatology, Karolinska University Hospital, Solna	Stockholm
Sweden	I73 Department of Infectious Diseases, Karolinska Institute, Karolinska University Hospital, Huddinge	Stockholm

Sponsors (2)

Lead Sponsor	Collaborator
Tripep AB	Inovio Pharmaceuticals

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate safety and tolerability of electroporation mediated i.m. delivery of CHRONVAC-C® in chronically HCV infected, treatment naive patients with low viral load.		From start of treatment to 24 weeks post treatment	Yes
Secondary	To provide information regarding dose related anti-viral immune response and dose related effect on viral load.		From start of treatment to 24 weeks post treatment	No